论文部分内容阅读
慢性粒细胞性白血病(简称慢粒),发病统计约占全部白血病的15％。多发生在20～50岁。尽管现代疗法在短期内显效颇高,但生存期尚不及急淋儿童长,故慢粒的预后并不理想。现代治疗的局限性 1865年首用砷剂治疗慢粒产生暂时的效果。1902年后使用放射疗法持续约50年。1953年推荐马利兰化疗以来,未再取得显著进展。慢粒确诊后未经治疗的中数生存期约19个月。用放疗和马利兰两组对照,其中数生存
Chronic myeloid leukemia (referred to as CML), incidence statistics account for about 15% of all leukemia. Occurs in 20 to 50 years old. Although modern therapies are highly effective in the short term, their survival is not as good as that of children with acute appetite. Therefore, the prognosis of CML is not satisfactory. Limitations of Modern Therapy The first treatment of CML with arsenic in 1865 produced a transient effect. After 1902 radiotherapy was used for about 50 years. Since 1953, Maryland chemotherapy has been recommended, no significant progress has been made. CML diagnosed untreated median survival of about 19 months. With radiotherapy and Maryland two groups of controls, the number of survival